Fractionated Stereotactic Radiotherapy in Patients With Acromegaly
Fractionated Stereotactic Radiotherapy in Patients With Acromegaly
Hypothesis: Fractionated stereotactic radiotherapy is a safe therapy for treatment of
 patients with acromegaly in terms of both tumour control and biochemical remission
An audit was done on 34 patients with acromegaly (consecutive cohorte) treated with
 fractionated stereotactic radiotherapy in Rigshospitalet/National University Hospital,
 Copenhagen, Denmark. All patients had MR control regularly to monitor tunour control, and
 biochemical control assessed by growth hormone measurements during an oral glucose tolerance
 test. Furthermore all other pituitary axes were tested for sufficiency and concomitant
 medication likewise registered. The 7 year interim analysis demonstrated an acceptable tumour
 control and biochemical remission profile, and most patient had subsequent withdrawal of
 somatostatin analogue- and growth hormone receptor antagonis therapy. The observational study
 will continue with a new update in approx 2 years
Inclusion Criteria:

 adults active acromegaly pituitary tumour on MRI biochemical activity -

 Exclusion Criteria:

 pregnancy no visible tumour on MRI

 -